Serum urate and cardiovascular events in the DCCT/EDIC study

Alicia J Jenkins, Barbara H Braffett, Arpita Basu, Ionut Bebu, Samuel Dagogo-Jack, Trevor J Orchard, Amisha Wallia, Maria F Lopes-Virella, W Timothy Garvey, John M Lachin, Timothy J Lyons, DCCT/EDIC Research Group

Abstract

In type 2 diabetes, hyperuricemia is associated with cardiovascular disease (CVD) and the metabolic syndrome (MetS), but associations in type 1 diabetes (T1D) have not been well-defined. This study examined the relationships between serum urate (SU) concentrations, clinical and biochemical factors, and subsequent cardiovascular events in a well-characterized cohort of adults with T1D. In 973 participants with T1D in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC), associations were defined between SU, measured once in blood collected 1997-2000, and (a) concurrent MetS and (b) incident 'any CVD' and major adverse cardiovascular events (MACE) through 2013. SU was higher in men than women [mean (SD): 4.47 (0.99) vs. 3.39 (0.97) mg/dl, respectively, p < 0.0001], and was associated with MetS features in both (men: p = 0.0016; women: p < 0.0001). During follow-up, 110 participants (11%) experienced "any CVD", and 53 (5%) a MACE. Analyzed by quartiles, SU was not associated with subsequent CVD or MACE. In women, SU as a continuous variable was associated with MACE (unadjusted HR: 1.52; 95% CI 1.07-2.16; p = 0.0211) even after adjustment for age and HbA1c (HR: 1.47; 95% CI 1.01-2.14; p = 0.0467). Predominantly normal range serum urate concentrations in T1D were higher in men than women and were associated with features of the MetS. In some analyses of women only, SU was associated with subsequent MACE. Routine measurement of SU to assess cardiovascular risk in T1D is not merited.Trial registration clinicaltrials.gov NCT00360815 and NCT00360893.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Figure 1
Figure 1
Distribution of serum urate concentrations in (A) 540 men and (B) 433 women with type 1 diabetes from the DCCT/EDIC cohort in 1997–2000. The vertical lines indicate the upper limit of normal range, 6.8 mg/dl.
Figure 2
Figure 2
Hazard ratios for risk of ‘any CVD’ and MACE in men and women with type 1 diabetes, according to serum urate quartiles (relative to the lowest quartile). Hazard ratios for ‘any CVD’ are shown in (A) for men and (B) for women; those for MACE are shown in (C) for men and (D) for women.

References

    1. de Oliveira EP, Burini RC. High plasma uric acid concentration: Causes and consequences. Diabetol. Metab. Syndr. 2012 doi: 10.1186/1758-5996-4-12.
    1. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken). 2012;64:1431–1446. doi: 10.1002/acr.21772.
    1. Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. Double diabetes: A distinct high-risk group? Diabetes Obes. Metab. 2019;21:2609–2618. doi: 10.1111/dom.13848.
    1. Chillaron JJ, Le-Roux JAF, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63:181–187. doi: 10.1016/j.metabol.2013.10.002.
    1. Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr. Opin. Rheumatol. 2014;26:176–185. doi: 10.1097/BOR.0000000000000033.
    1. Ndrepepa G. Uric acid and cardiovascular disease. Clin. Chim. Acta. 2018;484:150–163. doi: 10.1016/j.cca.2018.05.046.
    1. Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. Front. Biosci. (Landmark Ed). 2012;17:656–669. doi: 10.2741/3950.
    1. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30:707–712. doi: 10.2337/dc06-1982.
    1. Purnell JQ, Zinman B, Brunzell JD, DCCT/EDIC Research Group The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation. 2013;127(2):180–187. doi: 10.1161/CIRCULATIONAHA.111.077487.
    1. Sibley SD, Palmer JP, Hirsch IB, Brunzell JD. Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J. Clin. Endocrinol. Metab. 2003;88:3379–3384. doi: 10.1210/jc.2002-021693.
    1. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, et al. Impact of excessive weight gain on cardiovascular outcomes in Type 1 diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2017;40:1756–1762. doi: 10.2337/dc16-2523.
    1. Rothen M, Jenkins AJ, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ, DCCT/EDIC Research Group Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J. Diabetes Complications. 2008;22(3):153–163. doi: 10.1016/j.jdiacomp.2007.02.003.
    1. Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, Virella G, Lopes-Virella MF, DCCT/EDIC Research Group LDL-containing immune complexes in the DCCT/EDIC cohort: Associations with lipoprotein subclasses. J. Diabetes Complications. 2011;25(2):73–82. doi: 10.1016/j.jdiacomp.2010.03.001.
    1. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, DCC/EDIC Research Group Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: Associations with gender and glycemia. Diabetes Care. 2003;26(3):810–818. doi: 10.2337/diacare.26.3.810.
    1. DCCT-EDIC Research Group Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99–111. doi: 10.2337/diacare.22.1.99.
    1. DCCT Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401.
    1. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49:626–632. doi: 10.2337/diabetes.49.4.626.
    1. DCCT-EDIC Research Group Risk factors for cardiovascular disease in Type 1 diabetes. Diabetes. 2016;65:1370–1379. doi: 10.2337/db15-1517.
    1. Watts RW. Technical bulletin No. 31. Determination of uric acid in blood and in urine. Ann. Clin. Biochem. 1974;11:103–111. doi: 10.1177/000456327401100139.
    1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511. doi: 10.1161/01.CIR.0000052939.59093.45.
    1. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: Is it time for reappraisal? Curr. Hypertens. Rep. 2013;15:175–181. doi: 10.1007/s11906-013-0344-5.
    1. Harjutsalo V, Thomas MC, Forsblom C, Groop PH, FinnDiane Study G Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018;20:2759–2767. doi: 10.1111/dom.13456.
    1. Rathmann W, Hauner H, Dannehl K, Gries FA. Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab. 1993;19:159–166.
    1. Pilemann-Lyberg S, Hansen TW, Persson F, Theilade S, Singh Ahluwalia T, Frystyk J, et al. Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. Nephrol. Dial. Transpl. 2019;34:659–666. doi: 10.1093/ndt/gfy076.
    1. Vassalle C, Mazzone A, Sabatino L, Carpeggiani C. Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hyde? Diseases. 2016 doi: 10.3390/diseases4010012.
    1. Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: A systematic review and meta-analysis. Clin. Chem. Lab. Med. 2016;54:7–15. doi: 10.1515/cclm-2015-0523.
    1. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res. (Hoboken). 2010;62:170–180.
    1. Pilemann-Lyberg S, Lindhardt M, Persson F, Andersen S, Rossing P. Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. J. Diabetes Complications. 2018;32:470–473. doi: 10.1016/j.jdiacomp.2018.02.002.
    1. Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 2020;382(26):2493–2503. doi: 10.1056/NEJMoa1916624.
    1. Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care. 2010;33:2471–2473. doi: 10.2337/dc10-1007.
    1. Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, et al. Serum uric acid predicts vascular complications in adults with type 1 diabetes: The coronary artery calcification in type 1 diabetes study. Acta Diabetol. 2014;51:783–791. doi: 10.1007/s00592-014-0611-1.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться